


See "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies" on page 475-486.



Supplementary Fig. 5. Clinical remission at week 44 in patients who were refractory or intolerant to tumor necrosis factor-antagonist therapy (UNITI-1 patients). q12w, every 12 weeks; q8w, every 8 weeks.